| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P356 | DOI | 10.1001/ARCHINTE.1993.00410040045007 |
| P698 | PubMed publication ID | 8435027 |
| P50 | author | David T Felson | Q37393431 |
| Janet Pope | Q48742471 | ||
| P2093 | author name string | Anderson JJ | |
| P433 | issue | 4 | |
| P921 | main subject | meta-analysis | Q815382 |
| P304 | page(s) | 477-484 | |
| P577 | publication date | 1993-02-01 | |
| P1433 | published in | JAMA Internal Medicine | Q177428 |
| P1476 | title | A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure | |
| P478 | volume | 153 |
| Q42378585 | 6. Diabetic Nephropathy |
| Q44442616 | A model analysis of costs of blood pressure destabilization and edema associated with rofecoxib and celecoxib among older patients with osteoarthritis and hypertension in a medicare choice population |
| Q41880476 | A study of the interaction between ropranolol and NSAIDs in protein binding by gel filtration method |
| Q34474876 | A systematic review of the effect of paracetamol on blood pressure in hypertensive and non-hypertensive subjects |
| Q37785123 | AJC Editor's Consensus: Selective and Nonselective Nonsteroidal Anti-Inflammatory Drugs and Cardiovascular Risk |
| Q28196347 | Administration-time dependent effects of acetyl-salicylic acid on blood pressure in patients with mild essential hypertension |
| Q46029457 | Ambulatory blood pressure control with bedtime aspirin administration in subjects with prehypertension. |
| Q55429438 | American-Style Football and Cardiovascular Health. |
| Q35192912 | Analgesia in patients with ESRD: a review of available evidence |
| Q37762758 | Antihypertensive effects of aspirin: what is the evidence? |
| Q35570981 | Antihypertensive therapy: special focus on drug interactions |
| Q33702253 | Anti‑inflammatory effects of oxymatrine on rheumatoid arthritis in rats via regulating the imbalance between Treg and Th17 cells |
| Q37044230 | Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? |
| Q28212591 | Aspirin, NSAIDs, and COX-2 inhibitors in cardiovascular disease: possible interactions and implications for treatment of rheumatoid arthritis |
| Q43144878 | Aspirin, non-aspirin analgesics and the risk of hypertension in the SUN cohort |
| Q59305271 | Aspirina, analgésicos y riesgo de hipertensión arterial en la Cohorte SUN |
| Q74777726 | Back and leg pain in older adults. Presentation, diagnosis, and treatment |
| Q46679468 | COX-2 inhibitors and arterial hypertension: an analysis of spontaneous case reports in the Pharmacovigilance database |
| Q40715158 | Cannabis use and blood pressure levels: United States National Health and Nutrition Examination Survey, 2005-2012. |
| Q80186573 | Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen |
| Q38990657 | Cardiovascular Safety and Bleeding Risk Associated with Nonsteroidal Anti-Inflammatory Medications in Patients with Cardiovascular Disease |
| Q38851488 | Cardiovascular effects of cyclooxygenase-2 inhibitors: a mechanistic and clinical perspective |
| Q37808570 | Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications |
| Q28166985 | Cardiovascular prophylaxis with aspirin: costs of supply and management of upper gastrointestinal and renal toxicity |
| Q36439704 | Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences? |
| Q28298198 | Cardiovascular risk, hypertension, and NSAIDs |
| Q37049698 | Cardiovascular risk, hypertension, and NSAIDs. |
| Q30360728 | Clinical Pharmacology and Cardiovascular Safety of Naproxen |
| Q40589567 | Clinical presentation and treatment of arthritis in the aged. |
| Q36132575 | Combined lipoxygenase/cyclo-oxygenase inhibition in the elderly: the example of licofelone |
| Q34669789 | Common secondary causes of resistant hypertension and rational for treatment |
| Q28195068 | Coxibs--beyond the GI tract: renal and cardiovascular issues |
| Q37342183 | Cyclooxygenase-1 inhibition attenuates angiotensin II-salt hypertension and neurogenic pressor activity in the rat. |
| Q81489115 | Diastolic heart function in RA patients |
| Q33577179 | Diet and lifestyle risk factors associated with incident hypertension in women |
| Q33941101 | Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study |
| Q37762756 | Do the blood pressure effects of nonsteroidal antiinflammatory drugs influence cardiovascular morbidity and mortality? |
| Q35046519 | Does cyclooxygenase-2 affect blood pressure? |
| Q87075754 | Drug interactions in general dental practice--considerations for the dental practitioner |
| Q39268826 | Drug-Induced Hypertension: Focus on Mechanisms and Management |
| Q36920662 | Drug-induced cardiovascular disorders |
| Q41597437 | Drug-induced hypertension. Recognition and management in older patients |
| Q42728807 | Effect of short-term nonsteroidal antiinflammatory therapy on mean blood pressure. A prospective, randomized clinical trial |
| Q44193431 | Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis |
| Q28184682 | Effects of low-dose aspirin on blood pressure and endothelial function of treated hypertensive hypercholesterolaemic subjects |
| Q74060320 | Effects of low-dose aspirin on clinic and ambulatory blood pressure in treated hypertensive patients. Collaborative Group of the Primary Prevention Project (PPP)--Hypertension study |
| Q34574399 | Effects of nonsteroidal anti-inflammatory drug therapy on blood pressure and peripheral edema |
| Q36952569 | Elevated blood pressure and analgesic overuse in chronic daily headache: an outpatient clinic-based study from China |
| Q41757692 | Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury |
| Q46188985 | Evaluation of GW406381 for treatment of osteoarthritis of the knee: two randomized, controlled studies. |
| Q33805541 | Evidence based management of hypertension: What to do when blood pressure is difficult to control |
| Q46896465 | Gastro-intestinal problems and concomitant medication in NSAID users: additional findings from a questionnaire-based survey in Italy |
| Q40155507 | Gastrointestinal and Cardiovascular Risk of Nonsteroidal Anti-inflammatory Drugs |
| Q36523260 | Heart failure induced by non-cardiac drugs |
| Q36948503 | High-dose, but not low-dose, aspirin impairs anticontractile effect of ticagrelor following ADP stimulation in rat tail artery smooth muscle cells |
| Q45084706 | Hypertension emergency as a side-effect of taking NSAIDs |
| Q38980060 | Hypertension in Athletes and Active Populations |
| Q35015406 | Ibuprofen: pharmacology, efficacy and safety |
| Q38169058 | Impact of aspirin dosing on the effects of P2Y12 inhibition in patients with acute coronary syndromes. |
| Q35677376 | Inhibition of the Prostaglandin Transporter PGT Lowers Blood Pressure in Hypertensive Rats and Mice |
| Q34449825 | Lumiracoxib: the evidence of its clinical impact on the treatment of osteoarthritis. |
| Q43070761 | Management of pain in patients with multiple health problems: a guide for the practicing physician |
| Q24812557 | Myocardial dysfunction in rheumatoid arthritis: epidemiology and pathogenesis |
| Q57264419 | NSAID use and BP in treated hypertensives: a retrospective controlled observational study |
| Q26784322 | NSAIDs and Cardiovascular Diseases: Role of Reactive Oxygen Species |
| Q41702946 | NSAIDs and blood pressure. Clinical importance for older patients |
| Q41657126 | NSAIDs and increased blood pressure. What is the clinical significance? |
| Q40382739 | NSAIDs: what you don't know can hurt you. |
| Q33676719 | Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications |
| Q24657795 | New horizons and perspectives in the treatment of osteoarthritis |
| Q21195404 | Nitric oxide and cardiovascular effects: new insights in the role of nitric oxide for the management of osteoarthritis |
| Q26749687 | Non-Steroidal Anti-Inflammatory Drugs and Aspirin Therapy for the Treatment of Acute and Recurrent Idiopathic Pericarditis |
| Q36076845 | Non-steroidal Anti-inflammatory Drugs (NSAIDs) Use in Primary Health Care Centers in A'Seeb, Muscat: A Clinical Audit |
| Q60619176 | Non-steroidal anti-inflammatory drugs (NSAIDs) and hypertension treatment intensification: a population-based cohort study |
| Q41484950 | Non-steroidal anti-inflammatory drugs and risk of cerebrovascular events in patients with osteoarthritis: a nested case-control study |
| Q35083808 | Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors |
| Q84078873 | Non-steroidal anti-inflammatory drugs: use and co-treatment with potentially interacting medications in the elderly |
| Q35016179 | Nonnarcotic analgesic use and the risk of hypertension. |
| Q28386844 | Nonsteroidal Anti-Inflammatory Drugs and the Kidney |
| Q28079436 | Nonsteroidal Anti-inflammatory Drugs and Risk of Incident Heart Failure: A Systematic Review and Meta-analysis of Observational Studies |
| Q73744535 | Nonsteroidal anti-inflammatory drugs (NSAIDs) and blood pressure |
| Q41113125 | Nonsteroidal anti-inflammatory drugs and hypertension. The risks in perspective |
| Q38011618 | Nonsteroidal antiinflammatory drugs, acetaminophen, and hypertension |
| Q36481601 | OTC analgesics and drug interactions: clinical implications |
| Q44219610 | Older adults living with osteoarthritis: examining the relationship of age and gender to medicine use. |
| Q35795138 | Over-the-counter analgesics in older adults: a call for improved labelling and consumer education |
| Q55405502 | Pain Management in Pediatric Chronic Kidney Disease. |
| Q34031148 | Pain management |
| Q35573940 | Pain management in patients with chronic kidney disease |
| Q34001974 | Paracetamol: new vistas of an old drug |
| Q34723818 | Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs |
| Q44063519 | Physician-reported management of edema and destabilized blood pressure in cyclooxygenase-2-specific inhibitor users with osteoarthritis and treated hypertension |
| Q36760012 | Physiologic and pathophysiologic roles of lipid mediators in the kidney |
| Q27023475 | Piroxicam-β-cyclodextrin: a GI safer piroxicam |
| Q40998803 | Possible role for brain prostanoid pathways in the development of angiotensin II-salt hypertension in rats |
| Q31881389 | Prospects for changing the burden of nonsteroidal anti-inflammatory drug toxicity |
| Q39370448 | Race and hypertension. What is clinically relevant? |
| Q28168380 | Renal and cardiovascular effects of non-steroidal anti-inflammatories and selective cox 2 inhibitors |
| Q34137765 | Renal aspects of treatment with conventional nonsteroidal anti-inflammatory drugs versus cyclooxygenase-2-specific inhibitors |
| Q34126991 | Renal effects of cyclooxygyenase-2-selective inhibitors |
| Q37178937 | Review of the cardiovascular safety of COXIBs compared to NSAIDS. |
| Q36812587 | Rheumatoid arthritis and cardiovascular disease: an update on treatment issues |
| Q33895592 | Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection. |
| Q37464386 | Risk of stroke associated with nonsteroidal anti-inflammatory drugs |
| Q36559595 | Safe pharmacologic treatment strategies for osteoarthritis pain in African Americans with hypertension, and renal and cardiac disease. |
| Q37225756 | Salicylates dilate blood vessels through inhibiting PYK2-mediated RhoA/Rho-kinase activation |
| Q28165707 | Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program |
| Q37794972 | Should nonsteroidal anti-inflammatory drugs (NSAIDs) be prescribed to the older adult? |
| Q44887803 | Spontaneous reports of hypertension leading to hospitalisation in association with rofecoxib, celecoxib, nabumetone and oxaprozin |
| Q42722033 | Strategies for making analgesia safer: the role of comparative effectiveness research |
| Q58791320 | Studying additive interaction in a healthcare database: Case study of NSAIDs, cardiovascular profiles, and acute myocardial infarction |
| Q33755782 | Sumatriptan-naproxen fixed combination for acute treatment of migraine: a critical appraisal |
| Q36390266 | Systolic and pulse pressure associate with incident knee osteoarthritis: data from the Osteoarthritis Initiative. |
| Q41036582 | Tenidap: not just another NSAID? |
| Q34804676 | The demographics of chronic pain management |
| Q44010988 | The different patterns of blood pressure elevation by rofecoxib and nabumetone. |
| Q34167753 | The effects of lumiracoxib 100 mg once daily vs. ibuprofen 600 mg three times daily on the blood pressure profiles of hypertensive osteoarthritis patients taking different classes of antihypertensive agents |
| Q37209550 | The pathogenesis of diabetic nephropathy |
| Q38038453 | The role of the kidney in regulating arterial blood pressure. |
| Q36464352 | Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis |
| Q36059512 | Treatment strategies for osteoarthritis patients with pain and hypertension |
| Q43981433 | Update of ACR guidelines for osteoarthritis: role of the coxibs |
| Q37731873 | Usage patterns of 'over-the-counter' vs. prescription-strength nonsteroidal anti-inflammatory drugs in France |
| Q88491704 | Use of anti-inflammatory analgesics in sickle-cell disease |
| Q94601377 | [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?] |
| Q87516441 | [Clinical relevance of drug interactions between nonsteroidal antiinflammatory drugs (NSAIDs) and antihypertensives] |
| Q94601375 | [What do we know about the cardiovascular toxicity of the NSAIDs?] |
Search more.